Jacob T. Jackson

Jacob T. Jackson

Auto-generated profile, based on publicly available information

Jacob T. Jackson

Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Blood
Verified
Journal Article
Closed access
PDF file
NHNicole M. Haynes
Nicole M. Haynes
JTJoseph A. Trapani
Joseph A. Trapani
MTMichèle W. L. Teng
Michèle W. L. Teng
JJJacob T. Jackson
Jacob T. Jackson
LCLoretta Cerruti
Loretta Cerruti
Phil DarcyPhil Darcy
Phil Darcy
Tumor cells are usually weakly immunogenic as they largely express self-antigens and can down-regulate major histocompatability complex/peptide molecules and critical costimulatory ligands. The challenge for immunotherapies has been to provide vigorous immune effector cells that circumvent these tumor escape mechanisms and eradicate established tumors. One promising approach is to engineer T cells with single-chain antibody receptors, and since T cells require 2 distinct signals for optimal activation, we have compared the therapeutic efficacy of erbB2-reactive chimeric receptors that contain either T-cell receptor zeta (TCR-ζ) or CD28/TCR-ζ signaling domains. We have demonstrated that primary mouse CD8+ T lymphocytes expressing the single-chain Fv (scFv)–CD28-ζ receptor have a greater capacity to secrete Tc1 cytokines, induce T-cell proliferation, and inhibit established tumor growth and metastases in vivo. The suppression of established tumor burden by cytotoxic T cells expressing the CD28/TCR-ζ chimera was critically dependent upon their interferon gamma (IFN-γ) secretion. Our study has illustrated the practical advantage of engineering a T-cell signaling complex that codelivers CD28 activation, dependent only upon the tumor's expression of the appropriate tumor associated antigen.

17 May 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JJJacob T Jackson
Jacob T Jackson
YHYifang Hu
Yifang Hu
RLRuijie Liu
Ruijie Liu
FMFrederick Masson
Frederick Masson
ADAngela D'AMico
Angela D'AMico
GBGabrielle T. Belz
Gabrielle T. Belz
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 August 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JJJacob T. Jackson
Jacob T. Jackson
EMElisabeth Mulazzani
Elisabeth Mulazzani
SNStephen L. Nutt
Stephen L. Nutt
SMSeth L. Masters
Seth L. Masters
Phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2) is a critical signaling molecule activated downstream from a variety of cell surface receptors that contain an intracellular immunoreceptor tyrosine-based activation motif. These receptors recruit kinases such as Syk, BTK, and BLNK to phosphorylate and activate PLCγ2, which then generates 1D-myo-inositol 1,4,5-trisphosphate and diacylglycerol. These well-known second messengers are required for diverse membrane functionality including cellular proliferation, endocytosis, and calcium flux. As a result, PLCγ2 dysfunction is associated with a variety of diseases including cancer, neurodegeneration, and immune disorders. The diverse pathologies associated with PLCγ2 are exemplified by distinct genetic variants. Inherited mutations at this locus cause PLCγ2-associated antibody deficiency and immune dysregulation, in some cases with autoinflammation. Acquired mutations at this locus, which often arise as a result of BTK inhibition to treat chronic lymphocytic leukemia, result in constitutive downstream signaling and lymphocyte proliferation. Finally, a third group of PLCγ2 variants actually has a protective effect in a variety of neurodegenerative disorders, presumably by increased uptake and degradation of deleterious neurological aggregates. Therefore, manipulating PLCγ2 activity either up or down could have therapeutic benefit; however, we require a better understanding of the signaling pathways propagated by these variants before such clinical utility can be realized. Here, we review the signaling roles of PLCγ2 in hematopoietic cells to help understand the effect of mutations driving immune disorders and cancer and extrapolate from this to roles which may relate to protection against neurodegeneration.

28 February 2013 in Blood
Verified
Journal Article
Closed access
PDF file
CSCyril Seillet
Cyril Seillet
JJJacob T. Jackson
Jacob T. Jackson
KMKate A. Markey
Kate A. Markey
HBHugh J. M. Brady
Hugh J. M. Brady
GHGeoffrey R. Hill
Geoffrey R. Hill
GBGabrielle T. Belz
Gabrielle T. Belz
Antiviral immunity and cross-presentation is mediated constitutively through CD8α+ and CD103+ DCs. Development of these DC subsets is thought to require the transcription factors Irf8, Id2, Nfil3, and Batf3, although how this network is regulated is poorly defined. We addressed the nature of the differentiation blocks observed in the absence of these factors and found that although all 4 factors are required for CD103+ DC development, only Irf8 is essential for CD8α+ DCs. CD8α+ DCs emerged in the absence of Id2, Nfil3 and Batf3 in short-term bone marrow reconstitution. These “induced” CD8α+ DCs exhibit several hallmarks of classic CD8α+ DCs including the expression of CD24, Tlr3, Xcr1, Clec9A, and the capacity to cross-present soluble, cell-associated antigens and viral antigens even in the absence of Batf3. Collectively, these results uncover a previously undescribed pathway by which CD8α+ DCs emerge independent of Id2, Nfil3, and Batf3, but dependent on Irf8. Key Points Transcription factors Batf3, Id2, and Nfil3 are not essential for induced CD8α+ DC generation. Induced CD8α+ DCs can cross-present cellular antigens.

1 November 2005 in Blood
Verified
Journal Article
Closed access
PDF file
MMMaria Moeller
Maria Moeller
NHNicole M. Haynes
Nicole M. Haynes
Michael KershawMichael Kershaw
Michael Kershaw
JJJacob T. Jackson
Jacob T. Jackson
MTMichele W. L. Teng
Michele W. L. Teng
Phil DarcyPhil Darcy
Phil Darcy
Because CD4+ T cells play a key role in aiding cellular immune responses, we wanted to assess whether increasing numbers of gene-engineered antigen-restricted CD4+ T cells could enhance an antitumor response mediated by similarly gene-engineered CD8+ T cells. In this study, we have used retroviral transduction to generate erbB2-reactive mouse T-cell populations composed of various proportions of CD4+ and CD8+ cells and then determined the antitumor reactivity of these mixtures. Gene-modified CD4+ and CD8+ T cells were shown to specifically secrete Tc1 (T cytotoxic-1) or Tc2 cytokines, proliferate, and lyse erbB2+ tumor targets following antigen ligation in vitro. In adoptive transfer experiments using severe combined immunodeficient (scid) mice, we demonstrated that injection of equivalent numbers of antigenspecific engineered CD8+ and CD4+ T cells led to significant improvement in survival of mice bearing established lung metastases compared with transfer of unfractionated (largely CD8+) engineered T cells. Transferred CD4+ T cells had to be antigen-specific (not just activated) and secrete interferon γ (IFN-γ) to potentiate the antitumor effect. Importantly, antitumor responses in these mice correlated with localization and persistence of geneengineered T cells at the tumor site. Strikingly, mice that survived primary tumor challenge could reject a subsequent rechallenge. Overall, this study has highlighted the therapeutic potential of using combined transfer of antigen-specific gene-modified CD8+ and CD4+ T cells to significantly enhance T-cell adoptive transfer strategies for cancer therapy.

15 November 2002 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NHNicole M. Haynes
Nicole M. Haynes
JTJoseph A Trapani
Joseph A Trapani
MTMichele W. L. Teng
Michele W. L. Teng
JJJacob T. Jackson
Jacob T. Jackson
LCLoretta Cerruti
Loretta Cerruti
Phil DarcyPhil Darcy
Phil Darcy
A new strategy to improve the therapeutic utility of redirected T cells for cancer involves the development of novel Ag-specific chimeric receptors capable of stimulating optimal and sustained T cell antitumor activity in vivo. Given that T cells require both primary and costimulatory signals for optimal activation and that many tumors do not express critical costimulatory ligands, modified single-chain Ab receptors have been engineered to codeliver CD28 costimulation. In this study, we have compared the antitumor potency of primary T lymphocytes expressing carcinoembryonic Ag (CEA)-reactive chimeric receptors that incorporate either TCR-ζ or CD28/TCR-ζ signaling. Although both receptor-transduced T cell effector populations demonstrated cytolysis of CEA+ tumors in vitro, T cells expressing the single-chain variable fragment of Ig (scFv)-CD28-ζ chimera had a far greater capacity to control the growth of CEA+ xenogeneic and syngeneic colon carcinomas in vivo. The observed enhanced antitumor activity of T cells expressing the scFv-CD28-ζ receptor was critically dependent on perforin and the production of IFN-γ. Overall, this study has illustrated the ability of a chimeric scFv receptor capable of harnessing the signaling machinery of both TCR-ζ and CD28 to augment T cell immunity against tumors that have lost expression of both MHC/peptide and costimulatory ligands in vivo.